Donepezil Treatment and Changes in Hippocampal Structure in Very Mild Alzheimer Disease

Wang, Lei; Harms, Michael P.; Staggs, Jarrod M.; Xiong, Chengjie; Morris, John C.; Csernansky, John G.; Galvin, James E.

doi:10.1001/archneurol.2009.292

Cited by 24 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, when comparing treated and untreated AD patients, Fox et al [34] reported non-significant hippocampal volume change. Similarly, Wang et al [41] did not find significant differences in hippocampal volume or surface deformation between treated and untreated MCI patients. Their method of averaging the deformation within each subfield assumes homogeneous atrophy.…”

Section: Discussionmentioning

confidence: 88%

Evaluating Alzheimer’s Disease Progression Using Rate of Regional Hippocampal Atrophy

Frankó

Joly

2013

PLoS ONE

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is characterized by neurofibrillary tangle and neuropil thread deposition, which ultimately results in neuronal loss. A large number of magnetic resonance imaging studies have reported a smaller hippocampus in AD patients as compared to healthy elderlies. Even though this difference is often interpreted as atrophy, it is only an indirect measurement. A more direct way of measuring the atrophy is to use repeated MRIs within the same individual. Even though several groups have used this appropriate approach, the pattern of hippocampal atrophy still remains unclear and difficult to relate to underlying pathophysiology. Here, in this longitudinal study, we aimed to map hippocampal atrophy rates in patients with AD, mild cognitive impairment (MCI) and elderly controls. Data consisted of two MRI scans for each subject. The symmetric deformation field between the first and the second MRI was computed and mapped onto the three-dimensional hippocampal surface. The pattern of atrophy rate was similar in all three groups, but the rate was significantly higher in patients with AD than in control subjects. We also found higher atrophy rates in progressive MCI patients as compared to stable MCI, particularly in the antero-lateral portion of the right hippocampus. Importantly, the regions showing the highest atrophy rate correspond to those that were described to have the highest burden of tau deposition. Our results show that local hippocampal atrophy rate is a reliable biomarker of disease stage and progression and could also be considered as a method to objectively evaluate treatment effects.

show abstract

Section: Discussionmentioning

confidence: 88%

Evaluating Alzheimer’s Disease Progression Using Rate of Regional Hippocampal Atrophy

Frankó

Joly

2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The aim of this study was to compare hippocampal subfield volume differences between controls and drug-naïve subjects with AD with a somewhat larger sample size by using the automated hippocampal subfield segmentation method of Van Leemput et al 7 Indeed, a previous study revealed that the hippocampal atrophy rate might be affected by medications such as cholinesterase inhibitors. 8 We hypothesized that CA1 and subiculuar volumes would be smaller while other subfields would be spared in AD compared with controls.…”

mentioning

confidence: 99%

Automated Segmentation of Hippocampal Subfields in Drug-Naïve Patients with Alzheimer Disease

Lim¹,

Hong²,

Jung

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:Although a few automated hippocampal subfield segmentation methods have been developed, there is no study on the effects of the diagnosis of Alzheimer disease on the hippocampal subfield volume with in vivo MR imaging. The aim of this study was to investigate hippocampal subfield volume differences between drug-naïve subjects with AD and healthy elderly controls by using an automated hippocampal subfield segmentation technique.

show abstract

“…In another subgroup of MCI patients, there were no significant changes in annual percentage change in hippocampal atrophy, but less volumetric change was seen in treated patients when measures of whole-brain or periventricular volumes were used [74]. Preservation of hippocampal volume with decrements in untreated patients was found in a study of 18 AD patients treated with donepezil [75]. Similar subgroup studies of MCI patients from larger rivastigmine trials have shown that females and carriers of the BuChE wild-type genotype had significantly less gray and white matter brain volume loss than placebo MCI patients [76].…”

Section: Structural Mrimentioning

confidence: 96%

Central effects of cholinesterase inhibitors in Alzheimer’s disease: insights from advanced neuroimaging

Venneri¹,

Shanks²

2013

Imaging in Medicine

View full text Add to dashboard Cite

Donepezil Treatment and Changes in Hippocampal Structure in Very Mild Alzheimer Disease

Cited by 24 publications

References 27 publications

Evaluating Alzheimer’s Disease Progression Using Rate of Regional Hippocampal Atrophy

Evaluating Alzheimer’s Disease Progression Using Rate of Regional Hippocampal Atrophy

Automated Segmentation of Hippocampal Subfields in Drug-Naïve Patients with Alzheimer Disease

Central effects of cholinesterase inhibitors in Alzheimer’s disease: insights from advanced neuroimaging

Contact Info

Product

Resources

About